肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：TAK-117治疗晚期恶性肿瘤Ⅰ期临床试验结果

2017-09-05 MedSci MedSci原创

TAK-117晚期肿瘤临床试验
关注

CLIN CANCER RES近期发表了一篇文章，报道了PI3Kα选择抑制剂TAK-117治疗晚期恶性实体肿瘤的安全性，最大耐受剂量，药代动力学，药理学以及抗肿瘤活性等Ⅰ期临床试验结果。

CLIN CANCER RES近期发表了一篇文章，报道了PI3Kα选择抑制剂TAK-117治疗晚期恶性实体肿瘤的安全性，最大耐受剂量，药代动力学，药理学以及抗肿瘤活性等Ⅰ期临床试验结果。研究共纳入71例患者。患者接受口服TAK-117每天1次（100-300mg，n=24）或每周3天（周一、三、五（MWF），200-1200mg，n=27；周一、二、三（MTuW），200-900mg，n=20），周期21天。通过3+3设计进行剂量递增试验。研究结果表明，TAK-117每天1次与剂量限制3级以上ALT/AST转氨酶升高有关，导致耐受剂量范围较小（100-150mg每天）。使用MWF/MTuW剂量治疗时，直到最大耐受剂量900mg时无剂量限制ALT/AST升高出现，每周的药物剂量为150mg每天的2.6倍。每天1次/MWF/MTuW治疗患者的药物相关3级以上不良反应率为25%/22%/35%（高血糖率为0%/7%/15%）。TAK-117（100-1200mg）口服吸收快速，血浆药物半衰期约为11个小时。900mg MWF/MTuW一周总暴露量约为150mg每天的4倍。超过200mg出现p

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-18 41514487@qq.com

    #晚期恶性肿瘤#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-03-10 医生2402

    #I期临床#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-06-17 839640778

    #I期临床试验#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-12 mxc0712

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 忠诚向上

    好好看下.内容丰富

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 有备才能无患

    文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效.

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 luominglian113

    学习了.谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2066815, encodeId=0656206681502, content=<a href='/topic/show?id=425759831ae' target=_blank style='color:#2F92EE;'>#晚期恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59831, encryptionId=425759831ae, topicName=晚期恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Sep 18 16:33:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Mar 10 08:33:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Jun 17 05:33:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243136, encodeId=d61424313646, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLCl1NoqHGKCG3ichrqjRBLacc6IriaZe9LQSPDhQKMvgzGy2IvlLN8fcHAuWQ3O30YNfZu2C5CHice9w/0, createdBy=376e1607370, createdName=mxc0712, createdTime=Tue Sep 12 08:33:49 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240873, encodeId=80582408e3c8, content=好好看下.内容丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Sep 05 23:56:34 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240854, encodeId=d6dc240854d7, content=文章最后认为.与每天1次治疗方式相比.TAK-117间隔治疗安全性良好且可以实现更大的药物剂量和每周暴露量.TAK-117单药治疗疗效有限.应进一步研究TAK-117与其他药物联合治疗晚期实体肿瘤的疗效., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Sep 05 23:28:31 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240831, encodeId=b4f52408312d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:44:28 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240763, encodeId=4ec8240e6388, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160623/IMG576BCE3504BEE4493.jpg, createdBy=161a1711463, createdName=心愿, createdTime=Tue Sep 05 14:42:14 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 心愿

    学习了

    0